PDF(Pubmed)
Abstract：
The therapeutic potential of insect-derived bioactive molecules as anti-SARS-CoV-2 agents has shown promising results. Hymenopteran venoms, notably from Apis mellifera (honeybee) and Vespa orientalis (oriental wasp), were examined for the first time in an in vitro setting for their potential anti-COVID-19 activity. This assessment utilized an immunodiagnostic system to detect the SARS-CoV-2 nucleocapsid antigen titer reduction. Further analyses, including cytotoxicity assays, plaque reduction assays, and in silico docking-based screening, were performed to evaluate the efficacy of the most potent venom. Results indicated that bee and wasp venoms contain bioactive molecules with potential therapeutic effects against SARS-CoV-2.Nevertheless, the wasp venom exhibited superior efficacy compared to bee venom, achieving a 90% maximal (EC90) concentration effect of antigen depletion at 0.184 mg/mL, in contrast to 2.23 mg/mL for bee venom. The cytotoxicity of the wasp venom was assessed on Vero E6 cells 48 h post-treatment using the MTT assay. The CC 50 of the cell growth was 0.16617 mg/mL for Vero E6 cells. The plaque reduction assay of wasp venom revealed 50% inhibition (IC50) at a 0.208 mg/mL concentration. The viral count at 50% inhibition was 2.5 × 104 PFU/mL compared to the initial viral count of 5 × 104 PFU/mL. In silico data for the wasp venom revealed a strong attraction to binding sites on the ACE2 protein, indicating ideal interactions. This substantiates the potential of wasp venom as a promising viral inhibitor against SARS-CoV-2, suggesting its consideration as a prospective natural preventive and curative antiviral drug. In conclusion, hymenopteran venoms, particularly wasp venom, hold promise as a source of potential therapeutic biomolecules against SARS-CoV-2. More research and clinical trials are needed to evaluate these results and investigate their potential for translation into innovative antiviral therapies.
摘要：
昆虫来源的生物活性分子作为抗SARS-CoV-2药物的治疗潜力已显示出有希望的结果。膜翅目毒液,特别是来自蜜蜂（蜜蜂）和东方黄蜂（东方黄蜂），首次在体外环境中检查了它们的潜在抗COVID-19活性。该评估利用免疫诊断系统来检测SARS-CoV-2核衣壳抗原滴度降低。进一步分析,包括细胞毒性试验，斑块减少试验，和基于硅对接的筛查，进行评估最有效的毒液的功效。结果表明，蜜蜂和黄蜂毒液中含有对SARS-CoV-2具有潜在治疗作用的生物活性分子。然而，黄蜂毒液表现出优于蜂毒的疗效，在0.184mg/mL时达到抗原消耗的最大90％（EC90）浓度效应，相比之下，蜂毒为2.23mg/mL。使用MTT测定法在处理后48小时对VeroE6细胞评估黄蜂毒液的细胞毒性。对于VeroE6细胞,细胞生长的CC50为0.16617mg/mL。黄蜂毒液的噬斑减少测定显示在0.208mg/mL浓度下的50%抑制(IC50)。与5×104PFU/mL的初始病毒计数相比,50%抑制时的病毒计数为2.5×104PFU/mL。黄蜂毒液的计算机数据显示对ACE2蛋白上的结合位点有很强的吸引力，表明理想的互动。这证实了黄蜂毒液作为抗SARS-CoV-2的有前途的病毒抑制剂的潜力，表明其被认为是一种潜在的天然预防和治疗性抗病毒药物。总之,膜翅目毒液,尤其是黄蜂毒液,有望成为对抗SARS-CoV-2的潜在治疗性生物分子的来源。需要更多的研究和临床试验来评估这些结果，并调查它们转化为创新抗病毒疗法的潜力。
